Cytek Biosciences Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.11 billion
- Book Value:
- Revenue TTM:
- $166.06 million
- Operating Margin TTM:
- Gross Profit TTM:
- $100.97 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Cytek Biosciences Inc had its IPO on 2021-07-23 under the ticker symbol CTKB.
The company operates in the Healthcare sector and Medical Devices industry. Cytek Biosciences Inc has a staff strength of 682 employees.
Shares of Cytek Biosciences Inc opened at $8.29 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $7.98 - $8.36, and closed at $8.07.
This is a -1.47% slip from the previous day's closing price.
A total volume of 578,014 shares were traded at the close of the day’s session.
In the last one week, shares of Cytek Biosciences Inc have increased by +1.89%.
Cytek Biosciences Inc's Key Ratios
Cytek Biosciences Inc has a market cap of $1.11 billion, indicating a price to book ratio of 3.6527 and a price to sales ratio of 9.4122.
In the last 12-months Cytek Biosciences Inc’s revenue was $166.06 million with a gross profit of $100.97 million and an EBITDA of $-7410000. The EBITDA ratio measures Cytek Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cytek Biosciences Inc’s operating margin was -6.09% while its return on assets stood at -1.25% with a return of equity of -0.52%.
In Q1, Cytek Biosciences Inc’s quarterly earnings growth was a positive 6577.6% while revenue growth was a positive 5.8%.
Cytek Biosciences Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.01 per share while it has a forward price to earnings multiple of 370.3704 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cytek Biosciences Inc’s profitability.
Cytek Biosciences Inc stock is trading at a EV to sales ratio of 7.7323 and a EV to EBITDA ratio of 268.7414. Its price to sales ratio in the trailing 12-months stood at 9.4122.
Cytek Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $524.58 million
- Total Liabilities
- $56.52 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Cytek Biosciences Inc ended 2023 with $524.58 million in total assets and $0 in total liabilities. Its intangible assets were valued at $524.58 million while shareholder equity stood at $423.46 million.
Cytek Biosciences Inc ended 2023 with $13.01 million in deferred long-term liabilities, $56.52 million in other current liabilities, 136000.00 in common stock, $-23837000.00 in retained earnings and $19.04 million in goodwill. Its cash balance stood at $129.48 million and cash and short-term investments were $299.00 million. The company’s total short-term debt was $3,585,000 while long-term debt stood at $2.13 million.
Cytek Biosciences Inc’s total current assets stands at $425.62 million while long-term investments were $0 and short-term investments were $169.52 million. Its net receivables were $43.10 million compared to accounts payable of $5.28 million and inventory worth $69.50 million.
In 2023, Cytek Biosciences Inc's operating cash flow was $-168874000.00 while its capital expenditure stood at $505000.
Comparatively, Cytek Biosciences Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Cytek Biosciences Inc stock is currently trading at $8.07 per share. It touched a 52-week high of $16.05 and a 52-week low of $16.05. Analysts tracking the stock have a 12-month average target price of $14.25.
Its 50-day moving average was $9.21 and 200-day moving average was $11.67 The short ratio stood at 4.52 indicating a short percent outstanding of 0%.
Around 1706.4% of the company’s stock are held by insiders while 5510% are held by institutions.
Frequently Asked Questions About Cytek Biosciences Inc
Similar Industry Stocks (Medical Devices)
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.